Expect Something Extra From CVS Caremark Corporation (CVS)?

By uniquely combining behavioral sciences, clinical specialization, and actionable data, Express Scripts leverages its innovate approach to achieve healthier outcomes with safer and more affordable prescription. Express Scripts projects that U.S. spending on specialty prescription drugs will increase 67% by the end of 2015, and Express Scripts is ready to help lower increase in specialty drug spending and increase medication adherence rates for better health outcomes for patients.

Bottom line

While CVS Caremark might be negatively impacted by the return of customers at Walgreen’s stores, CVS Caremark will continue to benefit from the developing healthcare trends with its unique integrated business model. Investors can continue to expect more long-term growth with solid cash flows and stable dividend from CVS Caremark.

Nick Chiu has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts.

The article Expect Something Extra From CVS Caremark? originally appeared on Fool.com and is written by Nick Chiu.

Nick is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.